ASX - Delayed Quote AUD

Immutep Limited (IMM.AX)

0.0230 0.0000 (0.00%)

At close: October 30 at 4:10:11 PM GMT+11

Immutep Quarterly Activities Report Q1 FY27

GlobeNewswire 2d ago

IMMP
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

GlobeNewswire 3mo ago

IMM.AX
0.00%
MRK

IMMP
Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients

GlobeNewswire 5mo ago

IMM.AX
0.00%
IMMP
Immutep Receives Nasdaq Notice of Bid Price Deficiency

GlobeNewswire 5mo ago

IMM.AX
0.00%
^IXIC

IMMP
Immutep Quarterly Activities Report Q3 FY26

GlobeNewswire 5mo ago

IMM.AX
0.00%
IMMP
Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

GlobeNewswire 6mo ago

IMM.AX
0.00%
IMMP
Immutep Limited (IMMP) Receives FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma

Insider Monkey 6mo ago

IMM.AX
0.00%
IMMP
Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

GlobeNewswire 6mo ago

IMM.AX
0.00%
IMMP
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

GlobeNewswire 3mo ago

JNJ

CUE

GMAB.CO
Immutep Quarterly Activities Report Q4 FY26

GlobeNewswire 3mo ago

IMM.AX
0.00%
IMMP
Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

GlobeNewswire 4mo ago

IMM.AX
0.00%
IMMP
Immutep Receives A$2.16 million French R&D Tax Incentive

GlobeNewswire 3d ago

IMMP

U.S. markets closed

Immutep Limited (IMM.AX)

Immutep Quarterly Activities Report Q1 FY27

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients

Immutep Receives Nasdaq Notice of Bid Price Deficiency

Immutep Quarterly Activities Report Q3 FY26

Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Immutep Limited (IMMP) Receives FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma

Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

Immutep Quarterly Activities Report Q4 FY26

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

Immutep Receives A$2.16 million French R&D Tax Incentive